openPR Logo
Press release

Biosimilars Market Growth CAGR of 24.32% Research Report by Brandessence Market Research | Global Trends, Business Opportunity, Development, Features, Value, Share, Size and Regional Forecast 2021 to 2027

Market Overview:
Biosimilars Market is valued at USD 11.58 Billion in 2020 and expected to reach USD 53.13 Billion by 2027 with the CAGR of 24.32% over the forecast period.

Biosimilars is also referred as the follow-on biologics. Biosimilars are the biologic medical products which is highly similar to another already approved biological medicine which is available in the market. Biosimilar are the copied and licensed versions of those reference biologics products those have undergone patent expiration. Development and validation of biosimilars with reference biologics products are very crucial aspect of the overall development process. Biosimilars are approved as per the same standards of pharmaceutical quality, efficacy, safety that apply to all biological medicines.

However, biosimilars are differ from generics and are not treated as generics, as entire manufacturing process of biosimilar, right from the raw materials used in the manufacturing are different from generic products manufacturing. Similar to generic, biosimilar are the low-cost medicine and can be used in many treatment therapies including some of the most critical diseases like cancer, inflammatory bowel disease, anemia and autoimmune disorders including multiple sclerosis, psoriasis, rheumatoid arthritis, Crohn’s and among others.

Under solid legal framework, which is introduced in 2004 by European Union (EU), prepared dedicated route for the approval of biosimilars and hence in 2006, growth hormone somatropin got the first approval of EU as a biosimilar. Whereas, on March 6, 2015, Zarxio obtained the first approval of FDA for Sandoz's Zarxio is biosimilar to Amgen's Neupogen which was originally licensed in 1991.

Get Sample Copy of this Premium Report: https://brandessenceresearch.com/requestSample/PostId/1316

Market Top Companies:
Eli Lily & Company, Pfizer Inc., Sandoz International GMBH, Amgen, Inc., Hospira Inc., Actavis, Inc., Biocon Ltd., Cipla Ltd, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Stada Arzneimittel Ag, Celltrion, Inc., Wockhardt Ltd, Mylan, Inc and Others.

True North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL):

News: On Jan 06, 2020, Biocon Biologics India Ltd is the wholly owned subsidiary of Biocon has announced the dilution of its share and sell its 3% share to True North for USD 100 million, by valuing the unlisted subsidiaries at around USD 3.5 billion. Biocon Biologics is formed in December 2017 to house all Biocon’s’ biologics business including biosimilars that include monoclonal antibodies, recombinant insulins and novel biologics. Biocon is the parent company of Biocon Biologics India Ltd, company aim to list Biocon Biologics in the next few years in similar fashion to its contract research arm Syngene.

Biosimilars Market Segmentation:
By Product
Insulin
Recombinant human growth hormone (rhGH)
Granulocyte colony-stimulating factor
Interferon
Erythropoietin
Etanercept

Monoclonal antibodies
Rituximab
Infliximab
Adalimumab
Trastuzumab

Other Monoclonal Antibodies
Follitropin
Glucagon
Calcitonin
Teriparatide
Enoxaparin Sodium

By Type of Manufacturing
In-House Manufacturing
Contract Manufacturing

By Indication
Offsite Treatment
Oncology
Chronic Disorder
Autoimmune Disease
Blood Disorders
Infectious Disease
Other Diseases

Regional & Country Analysis: North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa.

Biosimilars Market Regional Analysis:
Europe is dominating the biosimilar market owing to early adaptation of biosimilars. For instance, European healthcare Agency is the pioneer in biosimilar, the establishment of favorable regulations such as Article 10(4) of Directive 2001/83/EC by the European Medical Association (EMA) has clarified the clinical aspect of biosimilars and the first biosimilar was approved by the EU in 2006. However, North America stands after Europe, In the year of 2018, 11 biosimilars have been approved by Food and Drug Administration (FDA).

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to relatively lower manufacturing costs, skilled labor and less complicated regulatory measures present in the region. The biosimilars market is currently witnessing active growth in regions, including countries like China, India, and Japan. Upsurge in FDA approval in India and finalized the biosimilars guidelines confined to the market for biosimilars production, sale, and consumption across the region.

Table of Contents:
Report Overview: It includes major players of the global Biosimilars market covered in the research study, research scope, and market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends: This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Biosimilars market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Biosimilars market are discussed.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Biosimilars market by application, it gives a study on the consumption in the global Biosimilars market by application.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles: Almost all leading players of the global Biosimilars market are profiled in this section. The analysts have provided information about their recent developments in the global Biosimilars market, products, revenue, production, business, and company.

Market Forecast by Production: The production and production value forecasts included in this section are for the global Biosimilars market as well as for key regional markets.

Market Forecast by Consumption: The consumption and consumption value forecasts included in this section are for the global Biosimilars market as well as for key regional markets.

Value Chain and Sales Analysis: It deeply analyzes customers, distributors, sales channels, and value chain of the global Biosimilars market.

Key Findings: This section gives a quick look at the important findings of the research study.

Request Methodology of the Report: https://brandessenceresearch.com/requestMethodology/PostId/1316

Contact Us:
Alan Ruffalo,
Corporate Sales: +44-2038074155
Email: sales@brandessenceresearch.com

About US:
Brandessence Market Research and Consulting Pvt Ltd
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market Growth CAGR of 24.32% Research Report by Brandessence Market Research | Global Trends, Business Opportunity, Development, Features, Value, Share, Size and Regional Forecast 2021 to 2027 here

News-ID: 2394262 • Views: 187

More Releases from Brandessence Market Research & Consulting Pvt ltd.

Neuroscience Antibodies and Assays Market Scenario, Gross Margin, Future Trends, …
Market Overview: Global Neuroscience Antibodies and Assays Market to reach USD 5.1 billion by 2025 Global Neuroscience Antibodies and Assays Market valued approximately USD 2.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2017-2025. The increasing automation of high-throughput screening and the availability of robust data management software tools, which enable researchers to develop systemic and process-oriented approaches toward neuroscience
Atomic Layer Deposition (ALD) Market Revenue, Top Players, Impact Analysis, Upco …
Market Overview: Global Atomic Layer Deposition (ALD) Market to reach USD 3.1 billion by 2025 Global Atomic Layer Deposition (ALD) Market valued approximately USD 1.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 12.04% over the forecast period 2017-2025. Increasing need for miniaturized components and Nano-technology, advancement in electronic sectors, increasing concern for global warming and emergence of new technologies like dye-sensitized solar cells, are
Diabetic Neuropathy Market Share, Company Profiles, Future Demand, Opportunities …
Market Overview: Global Diabetic Neuropathy Market to reach USD 8460.3 million by 2025. Global Diabetic Neuropathy Market valued approximately USD 4680 million in 2016 is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2017-2025. The growth of this market primarily driven by the ever-growing pool of geriatric population with diabetes. The rise in availability of suitable treatment options and the growing awareness on PDN
Circulating Tumor Cells (CTC) Market Global Trends, COVID-19 Impact Analysis, Co …
Market Overview: Global Circulating Tumor Cells (CTC) Market to reach USD 22.5 billion by 2025 Global Circulating Tumor Cells (CTC) Market valued approximately USD 5 billion in 2016 is anticipated to grow with a healthy growth rate of more than 18.20% over the forecast period 2017-2025. Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various

All 5 Releases


More Releases for Biosimilar

Global Biosimilar Drug Sales Market Report 2018
In this report, the global Biosimilar Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Free | Request Sample Copy of the Report @ https://bit.ly/2M8e47Z Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Biosimilar Drug for
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight
“Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014. Trastuzumab or
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.